Icatibant Gp-Pharm (Icatibant)

Icatibant is a bradykinin B2 receptor antagonist used in the management of hereditary angioedema.

• Hereditary angioedema (HAE) attacks: provides rapid relief of swelling episodes by blocking bradykinin‑mediated vascular permeability.

• Icatibant selectively and competitively binds to the bradykinin B2 receptor, preventing bradykinin from activating the receptor. This inhibition blocks the downstream signaling that leads to vasodilation and increased vascular permeability, thereby reducing the swelling characteristic of hereditary angioedema attacks.

Icatibant may cause a range of adverse reactions, most of which are related to its subcutaneous administration.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Erythema: redness around the injection area.
• Nausea: occasional feeling of queasiness.
• Headache: transient head discomfort.
• Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Hypotension: sudden drop in blood pressure.
• Angioedema: new swelling episodes unrelated to HAE.
• Thrombocytopenia: reduced platelet count.
• Severe infection at injection site: signs of cellulitis or abscess formation.

Before using Icatibant, consider the following safety measures.

• Pregnancy: safety not established; use only if potential benefit justifies the risk.
• Breastfeeding: unknown safety; weigh benefits against possible infant exposure.
• Renal impairment: monitor patients as clearance may be reduced.
• Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced effects.
• Estrogen‑containing therapies: may potentiate bradykinin‑mediated reactions; monitor closely.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or cardiovascular function.

Major Interactions (Avoid)

• ACE inhibitors: increase bradykinin levels and may heighten risk of angioedema.
• Neprilysin inhibitors: similarly raise bradykinin concentrations.
• Estrogen‑containing oral contraceptives: may exacerbate bradykinin‑mediated swelling.

Moderate Interactions (Monitor Closely)

• NSAIDs: can affect renal function and alter drug clearance.
• Diuretics: may influence blood pressure response.
• Other antihypertensives: monitor for additive hypotensive effects.
• Corticosteroids: may mask early signs of infection at injection site.
• Additional B2 receptor antagonists: assess cumulative pharmacologic impact.